{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:24:55Z","timestamp":1792790695326,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA253615"],"award-info":[{"award-number":["R01-CA253615"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K99-CA283299"],"award-info":[{"award-number":["K99-CA283299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shaughnessy Family Fund for Nano-ImmunoEngineering (nanoIE) at UCSD to N.F.S Cancer Therapeutics Training (CT2) program at the UCSD Moores Cancer Center to D.L.","id":[{"id":"https:\/\/ror.org\/01qkmtm61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current treatment options for ovarian cancer are limited to surgery to remove tumor tissues and chemotherapy. Although such treatments could provide a short period of remission, most patients still experience recurrent metastatic diseases. Here we present a nanotechnology-based personalized cancer vaccine that can be administrated to patients during the remission stage to prevent recurrent diseases. Autologous tumor cell lysates (TCL) are intriguing, personalized antigens that could be extracted from surgically recovered tumor tissues from patients containing all neoantigens. As proof of concept, we use TCL isolated from a murine ovarian cancer cell line. TCL are first encapsulated in liposomes (TCL-Lip), which are then attached to cowpea mosaic virus (CPMV), a plant virus as a potent adjuvant. Using the ID8-Defb29\/Vegf-a-Luc tumor model in female mice, the TCL-Lip-CPMV conjugate vaccine protects mice from tumor challenge by improving antigen processing and presentation, priming an adaptive anti-tumor immunity. Using ovalbumin (OVA) as a model antigen, OVA-Lip-CPMV vaccination protects mice from lung metastasis post-surgical removal of the primary B16F10-OVA dermal tumors. This research establishes a platform by combining two nanoparticle technologies into a single formulation for the simultaneous delivery of antigens and adjuvants, advancing the development of cancer vaccines and immunotherapies.<\/jats:p>","DOI":"10.1038\/s41467-025-60239-w","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T12:36:34Z","timestamp":1748608594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-6677","authenticated-orcid":false,"given":"Zhongchao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie K.","family":"Ledezma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Fernanda","family":"Affonso de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2323-2790","authenticated-orcid":false,"given":"Anthony O.","family":"Omole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-0481","authenticated-orcid":false,"given":"Nicole F.","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"60239_CR1","doi-asserted-by":"crossref","unstructured":"Korman, A. J., Garrett-Thomson, S. C. & Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 21, 509\u2013528 (2022).","DOI":"10.1038\/s41573-021-00345-8"},{"key":"60239_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/2326-6066.CIR-17-0057","volume":"5","author":"N Lonberg","year":"2017","unstructured":"Lonberg, N. & Korman, A. Masterful antibodies: Checkpoint blockade. Cancer Immunol. Res. 5, 275\u2013281 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"60239_CR3","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","volume":"162","author":"DR Littman","year":"2015","unstructured":"Littman, D. R. Releasing the brakes on cancer immunotherapy. Cell 162, 1186\u20131190 (2015).","journal-title":"Cell"},{"key":"60239_CR4","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi, J. et al. Safety and antitumor activity of anti\u2013PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015\u20134022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"60239_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211039899","volume":"13","author":"A Leary","year":"2021","unstructured":"Leary, A., Tan, D. & Ledermann, J. Immune checkpoint inhibitors in ovarian cancer: where do we stand?. Ther. Adv. Med. Oncol. 13, 17588359211039899 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"60239_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2017.00024","volume":"7","author":"T Worzfeld","year":"2017","unstructured":"Worzfeld, T. et al. The unique molecular and cellular microenvironment of ovarian cancer. Front. Oncol. 7, 24 (2017).","journal-title":"Front. Oncol."},{"key":"60239_CR7","unstructured":"Board, P. A. T. E. Ovarian Epithelial, fallopian tube, and Primary Peritoneal Cancer Treatment (PDQ\u00ae). In PDQ Cancer Information Summaries (National Cancer Institute (US), 2021)."},{"key":"60239_CR8","unstructured":"Arora, T., Mullangi, S. & Lekkala, M. R. Ovarian cancer. StatPearls (2022)."},{"key":"60239_CR9","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA: Cancer J. Clin.73, 17\u201348 (2023).","journal-title":"CA: Cancer J. Clin."},{"key":"60239_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5732\/cjc.014.10274","volume":"34","author":"C Della Pepa","year":"2015","unstructured":"Della Pepa, C. et al. Ovarian cancer standard of care: are there real alternatives?. Chin. J. Cancer 34, 17\u201327 (2015).","journal-title":"Chin. J. Cancer"},{"key":"60239_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1158\/0008-5472.CAN-12-1993","volume":"73","author":"L-H Tai","year":"2013","unstructured":"Tai, L.-H. et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cellsoncolytic virus inhibits surgery-induced NK cell dysfunction. Cancer Res. 73, 97\u2013107 (2013).","journal-title":"Cancer Res."},{"key":"60239_CR12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(03)01282-8","volume":"4","author":"JC Coffey","year":"2003","unstructured":"Coffey, J. C. et al. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 4, 760\u2013768 (2003).","journal-title":"Lancet Oncol."},{"key":"60239_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/BF02054059","volume":"39","author":"A Esp\u00ed","year":"1996","unstructured":"Esp\u00ed, A., Arenas, J., Garc\u00eda-Granero, E., Mart\u00ed, E. & Lled\u00f3, S. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Dis. Colon Rectum 39, 429\u2013434 (1996).","journal-title":"Dis. Colon Rectum"},{"key":"60239_CR14","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.4049\/jimmunol.1501657","volume":"195","author":"S Ilyas","year":"2015","unstructured":"Ilyas, S. & Yang, J. C. Landscape of tumor antigens in T cell immunotherapy. J. Immunol. 195, 5117\u20135122 (2015).","journal-title":"J. Immunol."},{"key":"60239_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/j.1460-2075.1987.tb04797.x","volume":"6","author":"MH Kraus","year":"1987","unstructured":"Kraus, M. H., Popescu, N., Amsbaugh, S. & King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6, 605\u2013610 (1987).","journal-title":"EMBO J."},{"key":"60239_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/sj.bjc.6603581","volume":"96","author":"D Pils","year":"2007","unstructured":"Pils, D. et al. In ovarian cancer the prognostic influence of HER2\/neu is not dependent on the CXCR4\/SDF-1 signalling pathway. Br. J. Cancer 96, 485\u2013491 (2007).","journal-title":"Br. J. Cancer"},{"key":"60239_CR17","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","volume":"94","author":"Y-T Chen","year":"1997","unstructured":"Chen, Y.-T. et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94, 1914\u20131918 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"60239_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth, R. E. & Jansen, K. Turning the corner on therapeutic cancer vaccines. npj Vaccines 4, 7 (2019).","journal-title":"npj Vaccines"},{"key":"60239_CR19","first-page":"66","volume":"36","author":"CA Ramos","year":"2013","unstructured":"Ramos, C. A. et al. Human papillomavirus type 16 E6\/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J. Immunother. (Hagerstown, MD, 1997) 36, 66 (2013).","journal-title":"J. Immunother. (Hagerstown, MD, 1997)"},{"key":"60239_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","volume":"17","author":"CL Slingluff Jr","year":"2011","unstructured":"Slingluff, C. L. Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?. Cancer J. (Sudbury, MA) 17, 343 (2011).","journal-title":"Cancer J. (Sudbury, MA)"},{"key":"60239_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/vaccines3020344","volume":"3","author":"CL-L Chiang","year":"2015","unstructured":"Chiang, C. L.-L., Coukos, G. & Kandalaft, L. E. Whole tumor antigen vaccines: where are we?. Vaccines 3, 344\u2013372 (2015).","journal-title":"Vaccines"},{"key":"60239_CR22","doi-asserted-by":"publisher","first-page":"17543","DOI":"10.1073\/pnas.2005794117","volume":"117","author":"CE Callmann","year":"2020","unstructured":"Callmann, C. E. et al. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. Proc. Natl Acad. Sci. USA 117, 17543\u201317550 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"60239_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.biomaterials.2016.10.047","volume":"113","author":"G-N Shi","year":"2017","unstructured":"Shi, G.-N. et al. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Biomaterials 113, 191\u2013202 (2017).","journal-title":"Biomaterials"},{"key":"60239_CR24","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","volume":"10","author":"FE Gonz\u00e1lez","year":"2014","unstructured":"Gonz\u00e1lez, F. E. et al. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum. Vaccines Immunother. 10, 3261\u20133269 (2014).","journal-title":"Hum. Vaccines Immunother."},{"key":"60239_CR25","first-page":"620","volume":"31","author":"P Hatfield","year":"2008","unstructured":"Hatfield, P. et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J. Immunother. (Hagerstown, MD, 1997) 31, 620 (2008).","journal-title":"J. Immunother. (Hagerstown, MD, 1997)"},{"key":"60239_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00262-005-0078-6","volume":"55","author":"M Salcedo","year":"2006","unstructured":"Salcedo, M. et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother. 55, 819\u2013829 (2006).","journal-title":"Cancer Immunol. Immunother."},{"key":"60239_CR27","first-page":"6445","volume":"61","author":"M Schnurr","year":"2001","unstructured":"Schnurr, M. et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 61, 6445\u20136450 (2001).","journal-title":"Cancer Res."},{"key":"60239_CR28","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.95.16.9482","volume":"95","author":"R Fields","year":"1998","unstructured":"Fields, R., Shimizu, K. & Mule, J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. USA 95, 9482\u20139487 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"60239_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1172\/JCI23373","volume":"115","author":"DE Speiser","year":"2005","unstructured":"Speiser, D. E. et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Investig. 115, 739\u2013746 (2005).","journal-title":"J. Clin. Investig."},{"key":"60239_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1078-0432.CCR-14-1790","volume":"21","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin. Cancer Res. 21, 286\u2013294 (2015).","journal-title":"Clin. Cancer Res."},{"key":"60239_CR31","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/s41423-020-0456-1","volume":"18","author":"C Fang","year":"2021","unstructured":"Fang, C. et al. Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine. Cell. Mol. Immunol. 18, 2211\u20132223 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"60239_CR32","doi-asserted-by":"publisher","first-page":"283ra252","DOI":"10.1126\/scitranslmed.aaa4306","volume":"7","author":"J Fu","year":"2015","unstructured":"Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 7, 283ra252\u2013283ra252 (2015).","journal-title":"Sci. Transl. Med."},{"key":"60239_CR33","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1039\/D0BM01219J","volume":"8","author":"S Shukla","year":"2020","unstructured":"Shukla, S. et al. The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine. Biomater. Sci. 8, 5489\u20135503 (2020).","journal-title":"Biomater. Sci."},{"key":"60239_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120914","volume":"275","author":"C Mao","year":"2021","unstructured":"Mao, C., Beiss, V., Fields, J., Steinmetz, N. F. & Fiering, S. Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors. Biomaterials 275, 120914 (2021).","journal-title":"Biomaterials"},{"key":"60239_CR35","doi-asserted-by":"crossref","unstructured":"Wang, C., Beiss, V. & Steinmetz, N. F. Cowpea mosaic virus nanoparticles and empty virus-like particles show distinct but overlapping immunostimulatory properties. J. Virol. 93, e00129\u201319 (2019).","DOI":"10.1128\/JVI.00129-19"},{"key":"60239_CR36","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s42003-024-06982-0","volume":"7","author":"AO Omole","year":"2024","unstructured":"Omole, A. O. et al. Cellular fate of a plant virus immunotherapy candidate. Commun. Biol. 7, 1382 (2024).","journal-title":"Commun. Biol."},{"key":"60239_CR37","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2217\/imt.09.70","volume":"1","author":"S Adams","year":"2009","unstructured":"Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy 1, 949\u2013964 (2009).","journal-title":"Immunotherapy"},{"key":"60239_CR38","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3389\/fphar.2018.00878","volume":"9","author":"X Cen","year":"2018","unstructured":"Cen, X., Liu, S. & Cheng, K. The role of toll-like receptor in inflammation and tumor immunity. Front Pharm. 9, 878 (2018).","journal-title":"Front Pharm."},{"key":"60239_CR39","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3389\/fimmu.2019.02388","volume":"10","author":"Z Urban-Wojciuk","year":"2019","unstructured":"Urban-Wojciuk, Z. et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front Immunol. 10, 2388 (2019).","journal-title":"Front Immunol."},{"key":"60239_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.actbio.2019.05.043","volume":"94","author":"TH Tran","year":"2019","unstructured":"Tran, T. H. et al. Toll-like receptor-targeted particles: a paradigm to manipulate the tumor microenvironment for cancer immunotherapy. Acta Biomater. 94, 82\u201396 (2019).","journal-title":"Acta Biomater."},{"key":"60239_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales, A., Eidinger, D. & Bruce, A. W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180\u2013183 (1976).","journal-title":"J. Urol."},{"key":"60239_CR42","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1126\/science.1138963","volume":"316","author":"V Mata-Haro","year":"2007","unstructured":"Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628\u20131632 (2007).","journal-title":"Science"},{"key":"60239_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","volume":"3","author":"H Hemmi","year":"2002","unstructured":"Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196\u2013200 (2002).","journal-title":"Nat. Immunol."},{"key":"60239_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.0105-2896.2004.00144.x","volume":"199","author":"B Pulendran","year":"2004","unstructured":"Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199, 227\u2013250 (2004).","journal-title":"Immunol. Rev."},{"key":"60239_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","volume":"30","author":"H Kumar","year":"2011","unstructured":"Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16\u201334 (2011).","journal-title":"Int. Rev. Immunol."},{"key":"60239_CR46","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1021\/acsnano.9b07865","volume":"14","author":"S Shukla","year":"2020","unstructured":"Shukla, S., Wang, C., Beiss, V. & Steinmetz, N. F. Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer. ACS Nano 14, 2994\u20133003 (2020).","journal-title":"ACS Nano"},{"key":"60239_CR47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nnano.2015.292","volume":"11","author":"PH Lizotte","year":"2016","unstructured":"Lizotte, P. H. et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotechnol. 11, 295\u2013303 (2016).","journal-title":"Nat. Nanotechnol."},{"key":"60239_CR48","doi-asserted-by":"crossref","unstructured":"Wang, C., Fiering, S. N. & Steinmetz, N. F. Cowpea mosaic virus promotes anti-tumor activity and immune memory in a mouse ovarian tumor model. Adv. Ther. (Weinheim) 2, 1900003 (2019).","DOI":"10.1002\/adtp.201900003"},{"key":"60239_CR49","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1021\/acs.molpharmaceut.8b00126","volume":"15","author":"PJ Hoopes","year":"2018","unstructured":"Hoopes, P. J. et al. Treatment of canine oral melanoma with nanotechnology-based immunotherapy and radiation. Mol. Pharm. 15, 3717\u20133722 (2018).","journal-title":"Mol. Pharm."},{"key":"60239_CR50","doi-asserted-by":"crossref","unstructured":"Alonso-Miguel, D. et al. Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer. J. Immunother. Cancer 10, e004044 (2022).","DOI":"10.1136\/jitc-2021-004044"},{"key":"60239_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101796","volume":"8","author":"YH Chung","year":"2021","unstructured":"Chung, Y. H., Park, J., Cai, H. & Steinmetz, N. F. S100A9-targeted cowpea mosaic virus as a prophylactic and therapeutic immunotherapy against metastatic breast cancer and melanoma. Adv. Sci. 8, 2101796 (2021).","journal-title":"Adv. Sci."},{"key":"60239_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308237","volume":"11","author":"YH Chung","year":"2024","unstructured":"Chung, Y. H. et al. Systemic administration of cowpea mosaic virus demonstrates broad protection against metastatic cancers. Adv. Sci. 11, 2308237 (2024).","journal-title":"Adv. Sci."},{"key":"60239_CR53","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/acsabm.0c00259","volume":"3","author":"BK Patel","year":"2020","unstructured":"Patel, B. K. et al. Cowpea mosaic virus (CPMV)-based cancer testis antigen ny-eso-1 vaccine elicits an antigen-specific cytotoxic T cell response. ACS Appl. Bio Mater. 3, 4179\u20134187 (2020).","journal-title":"ACS Appl. Bio Mater."},{"key":"60239_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/mp3002057","volume":"10","author":"AA Aljabali","year":"2013","unstructured":"Aljabali, A. A., Shukla, S., Lomonossoff, G. P., Steinmetz, N. F. & Evans, D. J. Cpmv-dox delivers. Mol. Pharm. 10, 3\u201310 (2013).","journal-title":"Mol. Pharm."},{"key":"60239_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.biomaterials.2016.12.030","volume":"121","author":"S Shukla","year":"2017","unstructured":"Shukla, S. et al. Plant viral nanoparticles-based HER2 vaccine: immune response influenced by differential transport, localization and cellular interactions of particulate carriers. Biomaterials 121, 15\u201327 (2017).","journal-title":"Biomaterials"},{"key":"60239_CR56","doi-asserted-by":"crossref","unstructured":"Simms, A., Zhao, Z., Cedrone, E., Dobrovolskaia, M. A. & Steinmetz, N. F. Cowpea mosaic virus intratumoral immunotherapy maintains stability and efficacy after long-term storage. Bioeng. Transl. Med. 9, e10693 (2024).","DOI":"10.1002\/btm2.10693"},{"key":"60239_CR57","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/nm1097","volume":"10","author":"JR Conejo-Garcia","year":"2004","unstructured":"Conejo-Garcia, J. R. et al. Tumor-infiltrating dendritic cell precursors recruited by a \u03b2-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10, 950\u2013958 (2004).","journal-title":"Nat. Med."},{"key":"60239_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00297-5","volume":"6","author":"JL Tanyi","year":"2021","unstructured":"Tanyi, J. L. et al. Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. npj Vaccines 6, 36 (2021).","journal-title":"npj Vaccines"},{"key":"60239_CR59","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Ortega-Rivera, O. A., Chung, Y. H., Simms, A. & Steinmetz, N. F. A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection. J. Mater. Chem. B. 11, 5429\u20135441 (2023).","DOI":"10.1039\/D2TB02355E"},{"key":"60239_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201702909","volume":"14","author":"B Meckes","year":"2018","unstructured":"Meckes, B., Banga, R. J., Nguyen, S. T. & Mirkin, C. A. Enhancing the stability and immunomodulatory activity of liposomal spherical nucleic acids through lipid-tail DNA modifications. Small 14, 1702909 (2018).","journal-title":"Small"},{"key":"60239_CR61","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1021\/bm8012742","volume":"10","author":"NF Steinmetz","year":"2009","unstructured":"Steinmetz, N. F. & Manchester, M. PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules 10, 784\u2013792 (2009).","journal-title":"Biomacromolecules"},{"key":"60239_CR62","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.chembiol.2004.04.011","volume":"11","author":"A Chatterji","year":"2004","unstructured":"Chatterji, A. et al. New addresses on an addressable virus nanoblock; uniquely reactive Lys residues on cowpea mosaic virus. Chem. Biol. 11, 855\u2013863 (2004).","journal-title":"Chem. Biol."},{"key":"60239_CR63","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1021\/acs.bioconjchem.0c00118","volume":"31","author":"J Park","year":"2020","unstructured":"Park, J., Chariou, P. L. & Steinmetz, N. F. Site-specific antibody conjugation strategy to functionalize virus-based nanoparticles. Bioconjug. Chem. 31, 1408\u20131416 (2020).","journal-title":"Bioconjug. Chem."},{"key":"60239_CR64","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jconrel.2013.04.023","volume":"172","author":"I Yildiz","year":"2013","unstructured":"Yildiz, I., Lee, K. L., Chen, K., Shukla, S. & Steinmetz, N. F. Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: cargo-loading and delivery. J. Control. Release 172, 568\u2013578 (2013).","journal-title":"J. Control. Release"},{"key":"60239_CR65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1006\/viro.1999.0038","volume":"265","author":"T Lin","year":"1999","unstructured":"Lin, T. et al. The refined crystal structure of cowpea mosaic virus at 2.8\u2009\u00c5 resolution. Virology 265, 20\u201334 (1999).","journal-title":"Virology"},{"key":"60239_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201700991","volume":"5","author":"AE Czapar","year":"2018","unstructured":"Czapar, A. E., Tiu, B. D. B., Veliz, F. A., Pokorski, J. K. & Steinmetz, N. F. Slow-release formulation of cowpea mosaic virus for in situ vaccine delivery to treat ovarian cancer. Adv. Sci. 5, 1700991 (2018).","journal-title":"Adv. Sci."},{"key":"60239_CR67","doi-asserted-by":"publisher","first-page":"869","DOI":"10.4049\/jimmunol.177.2.869","volume":"177","author":"VR Moulton","year":"2006","unstructured":"Moulton, V. R., Bushar, N. D., Leeser, D. B., Patke, D. S. & Farber, D. L. Divergent generation of heterogeneous memory CD4 T cells. J. Immunol. 177, 869\u2013876 (2006).","journal-title":"J. Immunol."},{"key":"60239_CR68","first-page":"e4352","volume":"69","author":"AM Wen","year":"2012","unstructured":"Wen, A. M. et al. Viral nanoparticles for in vivo tumor imaging. J. Vis. Exp. 69, e4352 (2012).","journal-title":"J. Vis. Exp."},{"key":"60239_CR69","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1021\/acsomega.8b00227","volume":"3","author":"R Patel","year":"2018","unstructured":"Patel, R., Czapar, A. E., Fiering, S., Oleinick, N. L. & Steinmetz, N. F. Radiation therapy combined with cowpea mosaic virus nanoparticle in situ vaccination initiates immune-mediated tumor regression. ACS Omega 3, 3702\u20133707 (2018).","journal-title":"ACS Omega"},{"key":"60239_CR70","doi-asserted-by":"crossref","unstructured":"Jiang, Y. et al. Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity. Adv. Mater. 32, 2001808 (2020).","DOI":"10.1002\/adma.202001808"},{"key":"60239_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-6591-5_2","volume":"1522","author":"H Zhang","year":"2017","unstructured":"Zhang, H. Thin-film hydration followed by extrusion method for liposome preparation. Methods Mol. Biol. 1522, 17\u201322 (2017).","journal-title":"Methods Mol. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60239-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60239-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60239-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T14:03:38Z","timestamp":1748613818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60239-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60239"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60239-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.F.S. is a co-founder and CEO of and has equity in PlantiosX Inc. She is also a co-founder of and has equity in Mosaic ImmunoEngineering Inc. and co-founder and manager of Pokometz Scientific LLC, under which she is a paid consultant to Flagship Labs 95 Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5047"}}